The US Department of Health and Human Services announced new programs intended to accelerate clinical trial timelines as competition for study execution intensifies from regions such as China and Australia. The flagship initiative, “SURPASS,” is designed to shift clinical development from a sequence of discrete phases toward a simulation-augmented, real-time adaptive seamless trials model, with ARPA-H also launching projects focused on speeding enrollment, building nationwide data infrastructure, and empowering patient participation. HHS cited operational friction as a core driver of delays and is positioning the US to regain speed and attractiveness for sponsors. The announcement comes after FDA efforts like Operation Trialblazer that similarly emphasize earlier-stage trial acceleration and qualified research infrastructure.